Chinese biotech PegBio’s shares fall 13% on Hong Kong IPO debut

A core product for Type 2 diabetes is expected to commercially launch in mainland China by the end of this year, subject to regulatory approval; CICC led the transaction.

PegBio, a Hangzhou-headquartered Chinese biotech firm, made its debut on the main board of the Hong Kong Stock Exchange HKEX on May 27. The stock opened at HK$13.5 $1.7 per share, 13.5% lower than the listing price of HK$15.6, which placed the initial public offering IPO offer at HK$300.8 million in total size.

PegBio's stock price closed at HK$11.56 per share. Hong Kong’s Hang Seng Index returned to over 23,400 points.

Pre-IPO investments were mainly backed by Chinese and Hong Kong-based investors, with an aggregate amount of approximately $50.3 million and Rmb1.05 billion $145.7 million, according to the firm. Yuan...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222